Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses

Experimental Lung Research

Volumn 37, Issue 3, 2011, Pages 131-143

  Olivier, Alicia K ^a   Gallup, Jack M ^a   Geelen, Albert Van ^a   Ackermann, Mark R ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Innate immunity; pulmonary pathology; respiratory syncytial virus; sheep defensin; surfactant protein; vascular endothelial growth factor

Indexed keywords

BETA DEFENSIN 1; INTERFERON BETA SERINE; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHATE BUFFERED SALINE; RECOMBINANT VASCULOTROPIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VIRUS MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM; INNATE IMMUNITY; INOCULATION; LAMB; LUNG ALVEOLUS CELL; LUNG LESION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN;

ANIMALS; ANIMALS, NEWBORN; BASE SEQUENCE; COLLECTINS; DEFENSINS; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; LUNG; RECOMBINANT PROTEINS; RESPIRATORY MUCOSA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; RNA, MESSENGER; RNA, VIRAL; SHEEP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952982724     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.484518     Document Type: Article

References (48)

1. Openshaw PJ, Tregoning JS: Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18:541-555. (Pubitemid 40995115)
2. Simoes EA: RSV disease in the pediatric population: Epidemiology, seasonal variability, and long-term outcomes.Manag Care. 2008;17:3-6, discussion 18-19.
3. Wu H, Pfarr DS, Losonsky GA, Kiener PA: Immunoprophylaxis of RSV infection: Advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103-123.
4. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
6. Hoeben A, Landuyt B, Highley MS,Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580. (Pubitemid 39658463)
7. Breen EC: VEGF in biological control. J Cell Biochem. 2007;102:1358-1367. (Pubitemid 350223939)
8. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA: Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168:639-648. (Pubitemid 43271161)
9. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992;3:211-220. (Pubitemid 23084552)
10. Mura M, dos Santos CC, Stewart D, Liu M: Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol. 2004;97:1605-1617. (Pubitemid 39425973)
11. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271:7788-7795. (Pubitemid 26111064)
12. Yamamoto H, Yun EJ, Gerber HP, Ferrara N, Whitsett JA, Vu TH: Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol. 2007;308:44-53. (Pubitemid 47087777)
13. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF: Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-1319.
14. Haeberle HA, Durrstein C, Rosenberger P, Hosakote YM, Kuhlicke J, Kempf VA, Garofalo RP, Eltzschig HK: Oxygenindependent stabilization of hypoxia inducible factor (HIF)-1 during RSV infection. PLoS One. 2008;3:e3352.
15. Lee CG, Yoon HJ, Zhu Z, Link H, Wang Z, Gwaltney JM, Landry M, Elias JA: Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. Am J Respir Cell Mol Biol. 2000;23:662-669.
16. De SilvaD,DagherH,Ghildyal R, Lindsay M, Li X, FreezerNJ, Wilson JW, Bardin PG: Vascular endothelial growth factor induction by rhinovirus infection. JMed Virol. 2006;78:666-672.
17. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS: The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20:108-119. (Pubitemid 44967956)
18. Olivier A, Gallup J, de Macedo MM, Varga SM, Ackermann M: Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. Int J Exp Pathol. 2009;90:431-438.
19. Mariassy AT, Plopper CG: Tracheobronchial epithelium of the sheep: I. Quantitative light-microscopic study of epithelial cell abundance, and distribution. Anat Rec. 1983;205:263-275. (Pubitemid 13113823)
20. Pack RJ, Al-Ugaily LH, Morris G: The cells of the tracheobronchial epithelium of the mouse: A quantitative light and electron microscope study. J Anat. 1981;132:71-84. (Pubitemid 11210854)
21. Scheerlinck JP, Snibson KJ, Bowles VM, Sutton P: Biomedical applications of sheep models: From asthma to vaccines. Trends Biotechnol. 2008;26:259-266.
22. Kawashima K, Meyerholz DK, Gallup JM, Grubor B, Lazic T, Lehmkuhl HD, Ackermann MR: Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus. Viral Immunol. 2006;19:316-323. (Pubitemid 44050330)
23. Hu A, Colella M, Tam JS, Rappaport R, Cheng SM: Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR. J Clin Microbiol. 2003;41:149-154. (Pubitemid 36098568)
24. Gallup JM, Ackermann MR: The 'PREXCEL-Q Method' for qPCR. Int J Biomed Sci. 2008;4:273-293.
25. Gallup JM, Ackermann MR: Addressing fluorogenic realtime qPCR inhibition using the novel custom Excel file system 'FocusField2-6GallupqPCRSet-upTool-001' to attain consistently high fidelity qPCR reactions. Biol Proced Online. 2006;8:87-152.
26. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk- 1/KDR activation. J Biol Chem. 1998;273:30336-30343. (Pubitemid 28545503)
27. Meyerholz DK, Gallup JM, Lazic T, de Macedo MM, Lehmkuhl HD, Ackermann MR: Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection. Viral Immunol. 2007;20:188-196. (Pubitemid 46608964)
28. Sano H, Kuroki Y: The lung collectins, SP-A and SPD, modulate pulmonary innate immunity. Mol Immunol. 2005;42:279-287. (Pubitemid 39626759)
29. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, Carmeliet P: Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8:702-710. (Pubitemid 34778723)
30. Bhandari V, Choo-Wing R, Lee CG, Yusuf K, Nedrelow JH, Ambalavanan N, Malkus H, Homer RJ, Elias JA: Developmental regulation of NO-mediated VEGF-induced effects in the lung. Am J Respir Cell Mol Biol. 2008;39:420-430.
31. Chen CM, Wang LF: High-dose vascular endothelial growth factor increases surfactant protein gene expressions in preterm rat lung. Early Hum Dev. 2007;83:581-584.
32. Hartshorn KL: Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed). 2:527-546.
33. Lofgren J, Ramet M, Renko M, Marttila R, Hallman M: Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis. 2002;185:283-289. (Pubitemid 34107240)
34. LeVine AM, Elliott J, Whitsett JA, Srikiatkhachorn A, Crouch E, DeSilva N, Korfhagen T: Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol. 2004;31:193-199. (Pubitemid 39095448)
35. Klotman ME, Chang TL: Defensins in innate antiviral immunity. Nat Rev Immunol. 2006;6:447-456.
36. Pino M, Kelvin DJ, Bermejo-Martin JF, Alonso A, Matias V, Tenorio A, Rico L, Eiros JM, Castrodeza J, Blanco-Quiros A, Ardura J, de Lejarazu RO: Nasopharyngeal aspirate cytokine levels 1 yr after severe respiratory syncytial virus infection. Pediatr Allergy Immunol. 2009;20:791-795.
37. Ekekezie II, Thibeault DW, Rezaiekhaligh MH, Norberg M, Mabry S, Zhang X, Truog WE: Endostatin and vascular endothelial cell growth factor (VEGF) in piglet lungs: Effect of inhaled nitric oxide and hyperoxia. Pediatr Res. 2003;53:440-446. (Pubitemid 36237399)
38. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM: Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;164:1971-1980. (Pubitemid 33152338)
39. Abadie Y, Bregeon F, Papazian L, Lange F, Chailley-Heu B, Thomas P,Duvaldestin P, Adnot S, Maitre B, Delclaux C: Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur Respir J. 2005;25:139-146. (Pubitemid 40207743)
40. Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, Haley KJ: Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2002;283:L585-L595.
41. Maitre B, Boussat S, Jean D, Gouge M, Brochard L, Housset B, Adnot S, Delclaux C: Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury. Eur Respir J. 2001;18:100-106. (Pubitemid 32720382)
42. Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A, Thickett DR: Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med. 2007;35:2164-2170. (Pubitemid 47326455)
43. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ: VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1001-L1010.
44. Meyerholz DK, Grubor B, Lazic T, Gallup JM, de Macedo MM, McCray PB Jr, Ackermann MR:Monocytic/macrophagic pneumonitis after intrabronchial deposition of vascular endothelial growth factor in neonatal lambs. Vet Pathol. 2006;43:689-694. (Pubitemid 44379945)
45. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL: VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol. 2004;287:L134-L142. (Pubitemid 38787660)
46. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, MarmeD:Migration of humanmonocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336-3343. (Pubitemid 26115364)
47. See H,Wark P: Innate immune response to viral infection of the lungs. Paediatr Respir Rev. 2008;9:243-250.
48. Sow FB, Gallup JM, Meyerholz DK, Ackermann MR: Gene profiling studies in the neonatal ovine lung show enhancing effects of VEGF on the immune response. Dev Comp Immunol. 2009;33:761-771.